A is an X-linked disorder caused by absent or dysfunctional factor VII1:C.
Schwl of Fledicine. Department of Pediatrics, Los Angeles, CA. @one marrod transplantation (BMT) i s being used increasingly for the treatment of pediatric malignanci~s and aplastic anemia. Conditioning regimens used prior to BMT may cause neurotoxicity, especially to the developing nervous system. W e report results of serial neurodevelopnental assessm t s of four patients transplanted during infamy for acute leukemia (AL) or aplastic anemia (AA).
Four consacutively studied children, a l l less than 1B months old at the time of BmT, were studied with the Gesell Developmental Schedules (GDS). and, later. with the Stanford-Binet (S-8) or Wechsler (WISC-R) intelligence tests and other standardized teats of Language, perceptim. and motor coordination.
A l l fwr children obtained average develomntal quotient scores on the G O S at the time of BNT. Tw patients with AL and one with AA, uho received total body irradiation, now shw at least average intelligence (SB IQ -107 and 138, and WISC-R IQ -128 respectively) more than five years after BmT. The other AA patient, 7 mnths old at BMT, obtained an S B 19 of 121, 23 m t h s after WIT. A l l four children show no abnormalities in perception, language, and motor coordination.
The post BMT davelopnent of these patients i s contrary to expectations that lethal chemoradiotherapy wwld likely produce neurologic disability in very young children and suggests that future therapeutic studies of infants and very young children using BFlT and intensive conditioning regimens are not contraindicated by the expectations of debilitating C N S sequelae. 760 Renewed i n t e r e s t i n the metabolism of 02 r a d i c a l s and Hz02 stems from awareness of t h e i r r o l e s , f o r example, i n BPD, W B C function, and c e r t a i n hemolytic anemias. Two means f o r disposal of H20 a r e : (a) c a t a l a s e and (b) the glucose-6-phosphate dehydrogenase fG6PD), NADPH, glutathione reductaselperoxidase pathway. A s r e f l e c t e d i n the present study by i n i t i a l r a t e s i n the spectrophotometric assay of Aebi, purif i e d c a t a l a s e from human red c e l l s and bovine l i v e r underwent p a r t i a l i n a c t i v a t i o n when d i l u t e d t o nanomolar concentrations a t pH 7. Inactivation occurred d e s p i t e the presence of bovine albumin and the use of p l a s t i c containers. The i n a c t i v a t i o n was prevented, but not promptly reversed, by t h e addition of NADPH. This e f f e c t seems t o be a second type of protection of c a t a l a s e by NADPH. Kirkman & Gaetani recently found t h a t c a t a l a s e contains t i g h t l y bound NADPH, which is slowly oxidized i n the process of preventing and reversing the i n a c t i v a t i o n (formation of compound 11) of c a t a l a s e by i t s own s u b s t r a t e , Hz02 (J. Biol. Chem. 262, i n press, 1987) . Human c a t a l a s e came t o be regarded a s a " f o s s i l enzyme" a s a r e s u l t of the r e l a t i v e l y benign nature of acatalasemia and the known s e n s i t i v i t y t o drug-induced peroxidative s t r e s s of G6PD-def i c i e n t red c e l l s , a deficiency a f f e c t i n g over 100 million people. Knowledge of catalase-NADPH i n t e r a c t i o n , however, allows r e -i n t e r p r e t a t i o n of e a r l i e r s t u d i e s and leads t o the conclusion t h a t human c a t a l a s e and pathway (b) a r e both responsible f o r H202 removal. Both a r e dependent on NADPH, which explains the p a r t i c u l a r s u s c e p t i b i l i t y of GbPD-deficient red c e l l s t o peroxidative s t r e s s .
METABOLIC IMPLICATIONS OF CATALASE
Arati Bhatnagar, Rathi V. Iyer University of Mississippi Medical Center, Department of Pediatrics, Jackson, MS An increase in serum iron levels and a decrease in serum unsaturated iron binding capacity (uIBC) were noted following the administration of cisplatinum t o 9 children with malignancies.
The mean serum iron concentration increased from a pretreatment level of 75.7t30.5 uglml t o a post treatment level of 162.1~65.3 u e r m l w i t h t h e f i r s t c i s p l a t i n u m t r e a t m e n t course(p<0.004). The ulBC concomittantly decreased from 1 8 1 . 9~3 3 . 7 u g / m l t o 8 6 . 4~4 4 . 6 ug/ml(p<0.0005).
Cummulative effect was noted following subsequent courses. The levels returned t o baseline values within 2-4 months following cessation of therapy in 6 children in whom follow up data was available. It is possible that this reversal of the ironluIBC ratio is the result of cisplatinum competition for iron binding sites to proteins. 
DDAVP (1-DESAMINO-8-D-ARGININE VASOPRESSIN) DECREASES OPERATIVE BLOOD LOSS IN PATIENTS UNDERGOING HARRING

r i o r t o Harrington rod s p i n a l fusion. On preoperative t e s t i n g , DDAVP increased f a c t o r V I I I coagulant a c t i v i t y , von Willebrand antigen, p l a t e l e t adhesiveness and prothrombin consumption and decreased t h e p a r t i a l thromboplastin time and t h e bleeding time (p<.0003). A t surgery, t h e drug
reduced blood l o s s by 32.3% (1681 + 901 m l i n t h e placebo group vs. 1134 5 593 ml i n t h e t r e a t e d group, p . 0 3 ) and s i m i l a r l y , reduced t h e requirement f o r concentrated red c e l l transfusions by 26.5% (3.36 + 1.64 u n i t s i n t h e placebo group vs. 2.50 + 0.97 u n i t s i n t h e t r e a t e d group, p . 0 4 ) .
Post-operatively, t h e drug reduced t h e duration o f analgesia from 201.5 5 83.0 hours i n t h e placebo group t o 149.0 5 64.0 hours i n t h e t r e a t e d group (p-.01), presumably by decreasing bleeding i n t o t h e s u r g i c a l wound. By multivariate regression a n a l y s i s , t h e b e s t t h r e e p r e d i c t o r s o f s u r g i c a l blood l o s s (p.024) and transfusion requirements (p.008) were t h e bleeding time, p l a t e l e t adhesiveness and t h e use o f DDAVP. I n conclusion, DDAVP shortens t h e bleeding time and decreases operative blood l o s s i n h e m s t a t ic a l l y normal subjects. To evaluate t h e r o l e of endogenous o p i a t e s i n chemtherapyinduced nausea and vomiting, t h e narcotic-antagonist naloxone was administered t o s i x p e d i a t r i c p a t i e n t s receiving cancer chemotherapy. Naloxone was administered by continuous i n t r avenous infusion a f t e r randomized, double-blind controlled assignment a t a dose of 0, 1 0 o r 40 ~g/kg/hour f o r 1 2 hours. Each p a t i e n t was studied f o r four consecutive and i d e n t i c a l courses o f chemotherapy (eight courses f o r each naloxone dose, o r 24 courses i n a l l ) . A dose-related increase i n nausea (nausea s c o r e 2.5 5 2.24, 3.83 + 2.73 and 5.75 2 2.86 p e r 12 hours, p . 0 0 3 ) , vomiting (emetic events 6.0 + 7.50, 8.08 + 6.71 and 10.3 2 8.91 p e r 12 hours, p-.035) and p a t i e n t aversion (course preference rank 1.5 5 0.45, 2.83 + 1.17 and 3.25 + 0.42 p e r four courses, p . 0 1 4 ) was observed. The infusion of naloxone i n t h e absence o f chemotherapy was without e f f e c t . These r e s u l t s support a r o l e f o r endogenous o p i a t e s i n regulati n g chemotherapy-induced nausea and vomiting, and further, suggest t h a t n a r c o t i c agents may be effective anti-emetics i n , t h i s s e t t i n g .
